ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

STX Shield Therapeutics Plc

1.48
-0.045 (-2.95%)
17 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.045 -2.95% 1.48 1.45 1.50 1.525 1.475 1.53 4,058,690 16:35:28
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 4.47M -40.44M -0.0522 -0.28 11.4M
Shield Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker STX. The last closing price for Shield Therapeutics was 1.53p. Over the last year, Shield Therapeutics shares have traded in a share price range of 1.475p to 12.75p.

Shield Therapeutics currently has 775,429,360 shares in issue. The market capitalisation of Shield Therapeutics is £11.40 million. Shield Therapeutics has a price to earnings ratio (PE ratio) of -0.28.

Shield Therapeutics Share Discussion Threads

Showing 23126 to 23147 of 23150 messages
Chat Pages: 926  925  924  923  922  921  920  919  918  917  916  915  Older
DateSubjectAuthorDiscuss
17/4/2024
12:59
They answer questions in these meetings, but not enough. They should show more info how to save money to get through the periods before H2 2025.
qipincha
17/4/2024
12:50
You can not ask any questions it’s staged and they pick the ones they posted themselves it’s a staged farce
best1467
17/4/2024
10:04
Very difficult to be a big player when your share price is languishing at all time lows and difficult to raise monies without more dilution.

A very promising Company years ago, management must take full responsibility for the current debacle

ny boy
16/4/2024
07:19
Results 30 April, when you can ask your Qs.
weatherman
15/4/2024
13:38
Execs and esp CEO (and maybe even NEDS) should take a pay cut they are way above average for the market cap and pocketing a significant chunk of revenue at every other shareholders expense.
cordwainer
12/4/2024
16:05
RI out of the frying pan and into the fire, white board members fail in darkest Africa, it's a pay back for colonialism!

TRP is a duffer, always looking for never ending money to finance, just confetti shares how many in issue now, must be 16 Billion + 🤡😂)0.02p should tell you everything, total nonsense.🆘⬇️ԍ18;🏻‍♀️Ԇ80;🙈

ny boy
11/4/2024
12:16
Missed a bullet now stood in front of an ak47 with TRPHa ha
bimbamboom
10/4/2024
12:33
Was it a Hardman researh report


??

riskyinvestor
10/4/2024
12:33
I was going to buy these at 8p last year because of a research report which said they are worth around 50p

I missed a bullet

Am in Tower Resources (TRP)

Where if funds allow I will be topping up every month if it stays at the 0.02p levels

riskyinvestor
09/4/2024
22:57
It was a half decent day until 4 o clock.Next update is crucial and I can't believe we can't exploit this FDA approved drug to create a profitable business and an share price many multiples of the current price.But then wtfdik.
husbod
09/4/2024
10:12
Yes, market size is tiny
qipincha
08/4/2024
09:31
I just bought in my ISA, many sold to realise the tax loss before the end of the tax year.

Business Metrics from the latest trading update !

· Cash: $13.9m as of 31 December 2023

· Total 2023 revenue and other income: $17.5m, a 2.8x increase over FY22

o Accrufer® revenue: $11.6m, a 3.1x increase over FY22

o Ex-U.S. revenue: $1.5m

o Other income revenue including Viatris milestone payments: $4.4m

· U.S. Q4 2023 Revenue: $4.3m

· Average net selling price: c.$145/prescription in H2 2023, an increase of c.21% compared with H1 2023

· Total 2023 Prescriptions: c.77k, a 3.1x increase over FY22



The company is making progress and the MCap shouldn’t be at this ridiculously low level. I believe either AOP Health or a pharma company will buy them eventually.

sam_
05/4/2024
18:52
Forget my last - it was just some stupid link someone gave me to an STX question but wrong company
bolitix
05/4/2024
18:26
Have they now changed to Argent Biofarm Ltd with a new CEO Roby Zomer or am i picking things up wrong
bolitix
05/4/2024
08:17
Same. Long and wrong. Written off the holding. It either goes to 0 with these fools in charge or magically realises it's value by someone else
reviewwworld
04/4/2024
18:19
Now i lost lots to these clowns so have now written that loss off. I did say this CEO would drag this share price near a penny some time ago. Now the worst could well be on the cards if they do a share exchange for the new company on a 1:10, 1:100 or even 1:1000 ratio to hype the price up on a Par so if 1:1000 the share price per share will be increased by a factor of 1000 to compensate but that will immediately drop lower. Hence, stay away from this company until it changes this CEO and its mindset.
bolitix
04/4/2024
09:24
I admit management screwed up big time on admission of data irregularities.
Was it Eddie who they pay minimum 60k a year to produce this exergerated phony report?

If they provide a good update and dont fool around which they now can not afford to do so, i expect share price to recover as new target numbers are more realistic

razoblade
04/4/2024
07:38
You are assuming they can add up. No one can trust their misleading statements. They knew when previous cfo left.Has Greg got his money out to buy shares. The man's a disgrace.
chester9
03/4/2024
22:56
the company should be able to manage their finance so long as they do it carefully!

there are also other options on the table.

but it is wisely to wait until they update their Q1 finance

qipincha
03/4/2024
17:20
Tim was Jeff Bezos compared to Greg the Bozo
reviewwworld
03/4/2024
14:51
GOING BUST GOING BUST GOING BUST GOING BUST GOING BUST GOING BUST
goforgold1
03/4/2024
14:33
Share price reflects almost unilateral conviction that the CEO (and fellow) management are possibly the most incompetent C-suite currently in employment.In situations like this, as I've said on this board, serve as a reminder that investing is about shareholder return. It doesn't matter if the company has the golden goose if they continuously just fry it's eggs for breakfast
reviewwworld
Chat Pages: 926  925  924  923  922  921  920  919  918  917  916  915  Older

Your Recent History

Delayed Upgrade Clock